QureTech Bio has received a substantial investment from Kempestiftelserna. A total of SEK 14 million is invested in the company by Kempestiftelserna along with the company’s largest shareholder, Nascent Invest.
Umeå based QureTech Bio, a biotechnology company developing novel antibiotics and anti-infectives, has appointed Markus Thor as the new Chief Executive Officer.
“Along with the team, I will strive to bring our substances to clinical trials”, he states.
QureTech Bio AB, a biotech company that develops novel antibiotics, has announced the appointment of Lennart Hansson as its new Chairman of the Board. Hansson succeeds Sven Bergström, who is stepping down after a successful tenure leading the company’s strategic direction.
Helén Fält, CEO of UBI-supported QureTech Bio AB, is busier than ever.
Umeå-based QureTech Bio AB receives support from the Swedish Research Council’s major investment ENABLE-2, which in collaboration with Vinnova gives small and medium-sized companies access to the ENABLE-2 platform to continue development of new antibiotics.
Umeå-based pharmaceutical development company QureTech Bio is hiring more people as it intensifies its work to combat antibiotic resistance.
“We recently received a major investment which has created long-term security in the company. With more people in place, we can now really push on and look to the future”, says Helén Fält, who was recently appointed the new CEO of QureTech Bio.
Umeå-based biotech company QureTech Bio has appointed Helén Fält as its new acting CEO, replacing Fredrik Almqvist, one of the company’s original founders.
“We have recently secured significant new investment and so it feels like the perfect time for Helén to come in and develop our business even further,” says Fredrik Almqvist.
Fredrik Almqvist, CEO of QureTech Bio based in Umeå in northern Sweden, is among thousands of researchers hoping to draw attention to the challenges of antibiotic resistance as part of World Antibiotic Awareness Week (18-24 November).
“It’s a problem that’s comparable to the climate crisis. We have to find new ways to kill antibiotic resistant disease-causing bacteria so we can save millions of lives every year,” he says.
Venture capital company Nascent Invest has bought shares in Umeå-based QureTech Bio as part of a targeted new share issue. The multi-million SEK investment will provide long-term security for the Swedish life science company as it continues its work to discover and develop new solutions to combat antibiotic-resistant bacteria.
“This investment means we can develop faster and take on more employees. As a result, we can get our medicines to market faster and hopefully save more lives,” says Fredrik Almqvist, CEO of QureTech Bio.
Umeå-based QureTech Bio has received preliminary approval for a patent application in the US for a drug candidate that helps treat tuberculosis.
“The US is a key market for us so this news really helps strengthen our position. We are at a very exciting stage right now,” says Fredrik Almqvist, CEO of QureTech Bio.
Umeå life science company QureTech Bio has received a SEK 3 million grant from the Swelife innovation programme (funded by the Swedish Government via Vinnova) to make antibiotic-resistant bacteria sensitive to different antibiotics again.
“We are delighted to receive this grant, as it will enable us to create a product that can help patients and save lives,” says Fredrik Almqvist, CEO of QureTech Bio.
Researchers from the Umea pharmaceutical research company Quretech Bio have been granted SEK 5 million by the Erling-Persson Family Foundation to make resistant bacteria sensitive to antibiotics again.
“We are delighted and extremely grateful. This money is vital in allowing us to continue conducting critical experiments” says Jörgen Johansson, Professor of Molecular Microbiology at Umeå University and Co-founder of Quretech Bio.
Researchers from Quretech Bio AB (Quretech Bio) in Umeå, who were awarded a research grant of approximately SEK 25 million in the summer, have been awarded additional funding of just over SEK 17 million this autumn (made up of SEK 7.5 million from the Swedish Research Council, SEK 8 million from the Erling Persson Family Foundation and SEK 2.1 million from Umeå University).
UBI Company Quretech Bio has reached a milestone in its development.
Recently, the company took its first investment capital and a cunning business development partner – a local player in Västerbotten.
Quretech, Hiloprobe and Inficure made the 30th of March a day to remember for Umeå Biotech Incubator. Beeing at three different events, in three parts of Sweden – they all managed to take home the main prize. An unprecedented hat trick that shows how strong the startup portfolio from Umeå really is.
Despite the name, the Biotech Umeå Investment Day is not only about raising money and not only strict biotech anymore. This year’s event had a fair representation of innovations from ICT, digital health and chemical. And it seems that the investors are also widening their scope and contributing with more value than just capital to upcoming startups.
The business coaches at Umeå Biotech Incubator have collected an impressive know-how over the years. With their inside position of some of the most innovative medical solusions they know how to get a life science company to thrive and grow.
QureTech Bio AB, a start-up at Umeå Biotech Incubator, developing first line drugs to combat antibiotic resistance and infectious diseases, won the BIO-Europe Spring Start-up Slam, in competition with 16 other presentations from 16 other Swedish life sciences start-up companies.
